Jane Street Group LLC Sells 16,550 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Jane Street Group LLC lowered its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 11.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 127,184 shares of the company’s stock after selling 16,550 shares during the quarter. Jane Street Group LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $1,431,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Oppenheimer Asset Management Inc. increased its holdings in Global X Genomics & Biotechnology ETF by 10.2% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 67,712 shares of the company’s stock worth $707,000 after acquiring an additional 6,260 shares during the last quarter. One Capital Management LLC increased its holdings in shares of Global X Genomics & Biotechnology ETF by 22.1% in the second quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock worth $7,102,000 after purchasing an additional 123,339 shares during the period. Sanctuary Advisors LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 2nd quarter valued at about $590,000. Centaurus Financial Inc. purchased a new position in shares of Global X Genomics & Biotechnology ETF during the second quarter worth about $146,000. Finally, James J. Burns & Company LLC increased its position in shares of Global X Genomics & Biotechnology ETF by 6.0% in the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock worth $207,000 after purchasing an additional 1,038 shares during the last quarter. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM opened at $9.84 on Friday. Global X Genomics & Biotechnology ETF has a 1-year low of $9.52 and a 1-year high of $12.53. The company has a market capitalization of $71.93 million, a P/E ratio of -4.21 and a beta of 1.03. The firm’s 50 day simple moving average is $10.40 and its 200 day simple moving average is $10.81.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.